Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. - Wikidata - wikimedia - TriplyDB

Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.

Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.

http://www.wikidata.org/entity/Q35926060

about

Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer Prognostic significance of miR-205 in endometrial cancer.Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.A Transition Zone Showing Highly Discontinuous or Alternating Levels of Stem Cell and Proliferation Markers Characterizes the Development of PTEN-Haploinsufficient Colorectal Cancer.Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors Long non-coding RNA derived miR-205-5p modulates human endometrial cancer by targeting PTEN.Flaxseed and its components differentially affect estrogen targets in pre-neoplastic hen ovaries Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas Glucose-regulated protein 94 deficiency induces squamous cell metaplasia and suppresses PTEN-null driven endometrial epithelial tumor development.Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors.TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets.PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells.TGF-β1 stimulates migration of type II endometrial cancer cells by down-regulating PTEN via activation of SMAD and ERK1/2 signaling pathways.PTEN and melanomagenesis.Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas.Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles.Systematic Analysis of Endometrial Cancer-Associated Hub Proteins Based on Text Mining Molecular analysis of isolated tumor glands from endometrial endometrioid adenocarcinomas.Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.Fucoidan elevates surface organic cation transporter 2 expression via upregulation of protein kinase A in uric acid nephropathy.Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach.Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future.The diagnostic role of PTEN and ARID1A in serous effusions.EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features.Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial.Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma.Dedifferentiated carcinoma with clear cell carcinoma of the endometrium: A case report.

P2860

Q21183964-E48A4145-F781-4B22-ACE6-592F4A67B4EF Q28085485-C6271422-8E89-4735-A871-C2CB039A37E4 Q30407709-0B974C32-1734-4304-8974-5BB1A9BC7235 Q33689293-07237AB3-F006-4BDA-B208-68647DE6513C Q34238901-42B8E127-40ED-4349-9DB4-AA18E2418EE5 Q34306540-2EF2A012-45CA-42CD-B684-7A3AC7A37315 Q34438555-6EE3C43E-2068-4764-A437-01E837120DBB Q34541232-A2526691-A3DB-4F5D-AA10-E47A0FBDCA6B Q35176084-69EE4696-519B-48EE-9912-337CA0CFDF04 Q35670782-83759B2E-E8DE-4C31-81E5-685A90813BE8 Q35986673-81378AF3-E629-4BBC-8CA3-50C17819EBA2 Q36096004-7B0A5001-9CB1-4840-80A1-BA2745CC946F Q36235829-9F872EE2-BC11-4CE9-BDC1-9954EAB03757 Q36420288-EF3E18CE-F6C2-43B1-9E54-49C6D0A96A7C Q36767559-6D49EB1E-60E2-4132-A4A7-DCD2C6F0E21F Q36841899-A8038330-5296-41AF-BC32-8B0D659100E6 Q37038863-CB21FFEF-1F36-4A4C-AEF5-EC2DA6646EE0 Q37046739-AD6FE80B-7007-4E4D-BFB4-98D30038797F Q37082536-739A3C7A-3D94-4B76-971A-8F1A4735DB48 Q37381834-75D3EAFC-9D46-492D-81D5-25E0D5B4225C Q37406889-217493D0-F59F-4299-87F1-080436C7E244 Q37520558-8FB90CF4-6039-47AF-A206-BF3725AA69C5 Q37641591-AB77CCFE-503A-48AE-B10F-A6A3733A0ABB Q38048884-D4AE859F-8B0D-4318-85D1-7FF8E58B6BDC Q38788729-12DBA073-3C06-4617-849C-AD357BA660DB Q40337301-1D7F5A5A-86CD-444A-84D0-77CDB02044C2 Q40543038-9543EF8B-0ED6-4354-9C5D-B992DDE53AC6 Q41138341-212E1FA0-4CBB-4ED5-9475-E0C843B0AC47 Q41149668-8A6CCE5B-67AD-4C18-9360-11D1315F6425 Q43110902-9946BDB5-4B13-4E6F-AA41-0257428B1779 Q46053202-581C2CA8-E21A-4FEC-8E55-C8F3662099B0 Q46764265-03122AC3-0EF3-4002-82BA-E64D15EBDC12 Q47097100-8820FF9A-2618-451F-8F20-CE1A96C91124 Q47163678-E2C92877-EF84-412D-881D-995FFD214430 Q47299584-7098CC01-0BFC-43CE-8853-B9D43BE76349 Q47369086-69C7D4DA-532A-47BF-8C9A-323C2EC82944 Q47763091-2C90A984-5565-488D-A51B-DC158377E5BE Q47908752-DF5F6385-13B4-43FA-8C87-B0752C5123E7 Q48233383-48F1D0E1-AEB4-4155-B76F-CAC2F0F1B3F8 Q50913291-42C22667-7622-4CBF-8439-6C01747CA4AB

P2860

Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.

http://www.wikidata.org/entity/Q35926060

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Clinical assessment of PTEN lo ...... y outperforms gene sequencing.

@ast

Clinical assessment of PTEN lo ...... y outperforms gene sequencing.

@en

type

label

Clinical assessment of PTEN lo ...... y outperforms gene sequencing.

@ast

Clinical assessment of PTEN lo ...... y outperforms gene sequencing.

@en

prefLabel

Clinical assessment of PTEN lo ...... y outperforms gene sequencing.

@ast

Clinical assessment of PTEN lo ...... y outperforms gene sequencing.

@en

P1433

Q35926060-DD7EEE2D-B1B4-44B1-9DEB-D7B0DD862CF3

P1476

Q35926060-33F88757-B657-43F6-9A81-E94C41087B00

P2093

Q35926060-06EF9A8F-9242-4E42-9D39-076EBF099D74

Q35926060-07922421-6246-4604-80F5-15BDC4E1A97A

Q35926060-16710898-3AC3-4E55-9197-B8C7170037BB

Q35926060-467C8EE0-B44B-4D59-88D9-151118477BE2

Q35926060-86732397-E112-4E11-99D5-E51950423DF1

Q35926060-ED70FA83-F19F-4341-91B6-18E45B4E4D8D

Q35926060-F7CF6D74-38A0-4931-B307-C4ED009F5290

P2860

Q35926060-0580C341-1ADE-44C1-9877-768E594EB9C1

Q35926060-097FB792-B05A-4168-B16A-1DCB8488654A

Q35926060-164211AD-90DF-4A1E-92EC-A0E16A886FAA

Q35926060-16989BC2-30AE-4504-9F44-4D10EFE6E345

Q35926060-188FEDA3-B432-4990-A8E1-1FA437C98E67

Q35926060-202D0737-2AFA-4079-AB83-8C679878E9D5

Q35926060-2112FDC0-A87B-44FD-97A8-3173E294B360

Q35926060-2C72ED3D-2780-45DD-9378-1854019036EB

Q35926060-34CCB916-D356-4F5A-9101-A50BB0289A2A

Q35926060-35B7D8CE-589A-4D37-8F0D-27BC35011346

P2888

Q35926060-6F433B7F-9C45-4FFB-83D3-943909FC8551

P304

Q35926060-0FFE11B4-D5B7-4E0C-9767-F9401BC99E77

P31

Q35926060-9766D33A-6344-4200-9F9A-C95B32C1B912

P356

Q35926060-79AB2E42-9ABE-48E1-9FCE-41792684CBE9

P433

Q35926060-00EB11AB-6A15-42EF-8C9E-B88D1582F20D

P478

Q35926060-CA34A7AE-076B-4B2C-A032-0DBDEC137F44

P577

Q35926060-2B266117-C208-4EAD-9EAB-078CCA47CCD6

P5875

Q35926060-07B62F26-626F-4ECC-9CDC-4853785E0A22

P698

Q35926060-C6A0BD0F-72B4-4691-9257-2A3945CFD6F9

P921

Q35926060-A347EB68-FB1A-4EDE-98B0-D0A613730F8F

P932

Q35926060-BF694DDD-8398-4B2D-8BB6-45EF372FC351

P356

MODPATHOL.2011.208

P1433

Modern Pathology

P1476

Clinical assessment of PTEN lo ...... y outperforms gene sequencing.

@en

P2093

Bedia A Barkoh

http://www.w3.org/2001/XMLSchema#string

Bojana Djordjevic

http://www.w3.org/2001/XMLSchema#string

Bryan T Hennessy

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

Jie Li

http://www.w3.org/2001/XMLSchema#string

Rajyalakshmi Luthra

http://www.w3.org/2001/XMLSchema#string

Russell R Broaddus

http://www.w3.org/2001/XMLSchema#string

P2860

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

PTEN1 is frequently mutated in primary endometrial carcinomas

MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer

AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.

Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma.

Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.

Mixed serous-endometrioid carcinoma of the uterus: pathologic and cytopathologic analysis of a high-risk endometrial carcinoma.

Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible

A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

P2888

modpathol.2011.208

P304

699-708

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2011.208

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221802491

http://www.w3.org/2001/XMLSchema#string

P698

22301702

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

P932

3341518

http://www.w3.org/2001/XMLSchema#string